Nora Liebers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nora Liebers has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Sascha Dietrich
10Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Duesseldorf, Germany
25 shared publications - Ana Nunes
Kite, a Gilead Company, Santa Monica, CA
23 shared publications - Anna Ossami Saidy
Department of Hematology and Cell Therapy Helios Klinikum Berlin‐Buch Berlin Germany
23 shared publications - Anna Sureda
Clinical Hematology Department, Institut Català d’Oncologia-Hospitalet, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain
23 shared publications - Ariane Boumendil
European Society for Blood and Marrow Transplantation Lymphoma Working Party, Paris, France
23 shared publications - Ben-Niklas Baermann
Department of Hematology, Oncology and Clinical Immunology, Medical Faculty, University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, D-40225 Düsseldorf, Germany
23 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Multivariate cox regression analysis of different treatments for PFS adjusting for baseline characteristics (full case analysis, ZUMA-2: n = 64, alloHCT: n = 250).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Multivariate cox regression analysis of different treatments for PFS adjusting for baseline characteristics (full case analysis, ZUMA-2: n = 64, alloHCT: n = 250).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Overall survival (OS) and progression-free survival (PFS) in the unmatched alloHCT cohort based on response status before alloHCT.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Overall survival (OS) and progression-free survival (PFS) in the unmatched alloHCT cohort based on response status before alloHCT.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Multivariate cox regression analysis of different treatments for OS adjusting for baseline characteristics (ZUMA-2: n = 64, alloHCT: n = 272)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Multivariate cox regression analysis of different treatments for OS adjusting for baseline characteristics (ZUMA-2: n = 64, alloHCT: n = 272)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Comparison of ZUMA-2 and alloHCT population for Overall survival (OS), Progression-free survival (PFS), Non-relapse mortality (NRM) and incidence of relapse (IR) in unmatched cohorts.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Comparison of ZUMA-2 and alloHCT population for Overall survival (OS), Progression-free survival (PFS), Non-relapse mortality (NRM) and incidence of relapse (IR) in unmatched cohorts.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Flow chart presenting inclusion and exclusion of patients used for final propensity score-matched analysis.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Flow chart presenting inclusion and exclusion of patients used for final propensity score-matched analysis.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Density plots for each covariate used for propensity score matching before and after matching.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Density plots for each covariate used for propensity score matching before and after matching.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S6 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Acute and chronic Graft-versus-host-disease in the total alloHCT cohort based on full case analysis.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Acute and chronic Graft-versus-host-disease in the total alloHCT cohort based on full case analysis.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Characteristics of transplant procedure in alloHCT cohort before and after matching.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Characteristics of transplant procedure in alloHCT cohort before and after matching.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S5 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Multivariate cause-specific hazard regression analysis of different treatments for IR in a competing risk setting adjusting for baseline characteristics (full case analysis, ZUMA-2: n = 64, alloHCT: n = 250).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Multivariate cause-specific hazard regression analysis of different treatments for IR in a competing risk setting adjusting for baseline characteristics (full case analysis, ZUMA-2: n = 64, alloHCT: n = 250).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Estimated conditional probabilities of receiving brexu-cel before (A) and after (B) matching.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Estimated conditional probabilities of receiving brexu-cel before (A) and after (B) matching.